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Abstract: Nitric oxide (NO) is a colorless gas
with high affinity to ferrous hemoproteins.
This simple molecule is a powerful messenger
in the body. This study reviews a literature
search using keywords and abstracts in
English through Medline. Recent advances in
the therapeutic uses of inhaled nitric oxide in
lung diseases and other pathologic states
urges the efficient and convenient use of nitric
oxide in hospital practice. In addition,
methods of inhaled nitric oxide delivery,
chemiluminescence and electrochemical
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Introduction
Nitric oxide (NO) is a multipotent endogenous
messenger molecule that is extensively involved in the
regulation of vascular tone. Gaseous nitric oxide was
considered as an environmental pollutant for decades. Its
properties for the dilation of blood vessels were identified
by Furchgott and Zawadzki in 1980 (1). In the early
1990s nitric oxide’s role in biological systems came to be
appreciated. “Science” journal declared nitric oxide as the
molecule of the year in 1992. The importance of this
molecule was confirmed when in 1998 the Nobel Prize
for medicine was awarded to L.J. Ignarro and two other
pharmacologists: R. F. Furchgott and F. Murad. Our
current understanding is that NO is a ubiquitous
substance that not only plays a major role in vasodilation,
but also affects the physiology of all organ systems.
Excellent recent review articles on NO have been
published (2,3). This review will emphasize the
measurement methods of NO, including delivery systems
of inhaled NO to patients. The adverse effects and toxicity
of nitric oxide clinical applications will be reviewed in a
subdivision of the subsequent study that will mainly
discuss the therapeutic uses of nitric oxide.
The Nobel Prize committee cited Furchgott's 1980
experiment that showed a drug, acetylcholine, could
widen blood vessels, but only if the layer of cells lining the

analyzers were reviewed. The performance
characteristics of different equipment were
compared. The novel methods of nitric oxide
measurements that utilize simple and cheaper
equipment were discussed. This study
provides necessary information prior to a
discussion on various clinical applications of
inhaled nitric oxide for therapeutic uses.
Key Words: nitric oxide, inhaled nitric oxide
measurements, electrochemical analyzer,
chemiluminescence analyzer

vessel was intact.(1) From this, Furchgott concluded that
those cells, the endothelium, must produce some signals
that relaxed the smooth muscle cells in blood vessels.
Furchgott called this signal "endothelium-derived relaxing
signal," or EDRF. But it was Ignarro who concluded, after
a brilliant series of analyses in 1986, that nitric oxide was
the elusive EDRF (4). Murad was cited for showing that
the gas could regulate important cellular functions (5).
Occurring throughout the body, nitric oxide performs
a number of regulatory tasks, including battling
infections, preventing the formation of blood clots, acting
as a signal molecule in the nervous system and controlling
blood flow to a number of organs. Ignarro discovered the
principle that allowed pharmaceutical researchers to
create the anti-impotency drug Viagra (6).

Materials and Methods
Medline databases were searched using the internet at
the PubMed-National Library of Medicine (U.S.A.) medical
database site. The keywords were searched for in the
period from January 1, 1990 through December 29,
2000. The restrictions were English language and English
abstracted articles. The literature was reviewed and the
different methods of inhaled nitric oxide delivery
techniques were compared.
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Biology and Mechanism of Action: Nitric oxide is a
colorless gas with high lipid and water solubility. It is
produced endogenously in the endothelium from Larginine by the enzyme NO synthase (NOS). L-arginine
and oxygen serve as substrates for NOS to produce nitric
oxide and L-citrulline (7). Nitric oxide has high binding
affinity for iron and iron-containing compounds. The
physiologic actions of NO are mediated by the activation
of the soluble guanylate cyclase to form cyclic guanosine
monophosphate (c-GMP), which causes vascular smooth
muscle relaxation by decreasing the concentration of free
calcium in the smooth muscle cytosol and resulting in
vasodilatation (8). Once endogenous NO is released into
the bloodstream, it reacts with iron in the hemoglobin.
This leads to the conversion of hemoglobin to
methemoglobin, which is converted to hemoglobin and
nitrite or nitrate by methemoglobin reductase. The latter
two products are nonvasoactive and excreted by the
kidneys (9). The half–life of nitric oxide in vivo is 0.1 to
5 seconds and is limited by its concentration and the
availability of oxygen, superoxide anion, protein, and
hemoglobin. Nitric oxide has several pathways of
metabolic inactivation. In the gas phase, nitric oxide
mixed with oxygen results in the formation of nitrogen
dioxide. In the liquid phase, nitric oxide interacts with
superoxide anion radical (O2 ) to produce peroxynitrite
(OONO-), which is cytotoxic. Peroxynitrite damages DNA,
induces lipid peroxidation and reacts with proteins. It also
reacts with the phenolic residues of tyrosine, resulting in
the formation of nitrotyrosine (10).
Physiological Effects: Nitric oxide has a wide
spectrum of physiological activity. Its formation in
vascular endothelial cells, in response to chemical stimuli
and to physical stimuli, such as shear stress, maintains a
vasodilator tone that is essential for the regulation of
blood flow and pressure. NO produces systemic and
pulmonary vascular relaxation and controls cardiac output
and the distribution of coronary, cerebral, and renal
circulation (11). It plays a central role in the inflammatory
cascade, inhibits leukocyte adhesion and modulates
smooth muscle cell proliferation (12). Nitric oxide is
involved in host defense and immunologic response. NO
generation was first observed in activated macrophages,
where it contributes to their cytotoxicity against tumor
cells, bacteria, viruses or other invading organisms.
Cytotoxic actions also result from its inhibitor actions on
key enzymes in the respiratory chain. NO inhibits platelet

472

adhesion and aggregation and prolongs bleeding time. In
the central nervous system, NO functions as a
neurotransmitter in many physiological functions,
including the formation of memory, coordination
between neuronal activity and blood flow and modulation
of pain. It modulates carbon dioxide responsiveness of the
cerebral vasculature (13). In the peripheral nervous
system, in the nonadrenergic and noncholinergic neurons,
nitric oxide relaxes smooth muscle cells of the
gastrointestinal tract, bronchial tree and penile corpora
cavernosa (14). NO exhibits both pro- and antiinflammatory effects and is also involved in the
modulation of ischemia/reperfusion tissue injury (15). It
is implicated in myometrial relaxation in pregnancy and
nitroglycerin therapy for tocolysis.
NO Measurement Methods and The Comparison
of Different Methods for Safe and Accurate Inhaled
Nitric Oxide (iNO) Delivery Systems: Nitric oxide
measurements in human subjects can be divided into two
subgroups:
1) Inhaled nitric oxide measurements: Inhaled NO
(iNO) is a selective pulmonary vasodilator predominantly
found in the vascular beds supplying ventilated alveoli;
thereby
improves
ventilation/perfusion
(V/Q)
relationships and reduces venous admixture in the
pulmonary vasculature, NO is rapidly absorbed by
hemoglobin, neutrophils, and platelets, preventing any
significant systemic vasodilatation. For delivery: A)
Delivery system including ventilator,circuits with
appropriate modules for iNO delivery. B) iNO
measurement by chemiluminescence and electrochemical
techniques.
A) Systems for delivery of NO: In this study, the
review of Medline literature showed 138 cited abstracts
about delivery systems in the English language. Various
systems to administer inhaled nitric oxide have been used
in patients and experimental animals. A lung model to
evaluate five NO delivery systems during mechanical
ventilation with various ventilatory patterns was prepared
(16). Four different injection systems were mentioned; a)
NO injected either into the inspiratory circuit 90 cm
proximal to the Y piece, b) directly at the Y piece, c)
delivered either continuously or d) only during the
inspiratory phase (16). Alternatively, NO was mixed with
air using a blender and delivered to the high-pressure air
inlet of the ventilator. Nitric oxide concentration was
measured from the inspiratory limb of the ventilator
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circuit and the tracheal level using rapid- and slowresponse chemiluminescence analyzers. The ventilator
was set for constant-flow volume control ventilation,
pressure control ventilation, pressure support ventilation,
or synchronized intermittent mandatory ventilation. Tidal
volumes of 0.5 L and 1 L were evaluated with inspiratory
times of 1 s and 2 s. The system that premixed NO
proximal to the ventilator was the only one that
maintained constant NO delivery regardless of ventilatory
pattern. The other systems delivered variable NO
concentrations during pressure control ventilation and
spontaneous breathing modes. Systems that injected a
continuous flow of NO delivered peak NO concentrations
greater than the calculated dose. These variations were
not apparent when a slow-response chemiluminescence
analyzer was used. NO delivery systems that inject NO at
a constant rate, either continuously or during inspiration
only, into the inspiratory limb of the ventilator circuit
produce highly variable and unpredictable NO delivery
when inspiratory flow is not constant. Such systems may
deliver a very high NO concentration to the lungs, which
is not accurately reflected by measurements performed
by slow-response analyzers (17).
Continuous flow delivery of nitric oxide into the circuit
of a phasic-flow ventilator results in marked inspiratory
nitric oxide concentration fluctuation that is not detected
by a slow-response chemiluminescence analyzer.
Moreover, nitric oxide concentration fluctuation can
influence the accuracy of the chemiluminescence
measurements. These effects can be diminished by using
additional mixing chambers to facilitate a stable gas
concentration. As these mixing volumes increase, the
contact time of nitric oxide with oxygen, and an increase
of nitrogen dioxide, has to be taken into account (18,19).
The application of NO close to the endotracheal tube is
associated with a much faster response of the actual
inspired NO concentration to dosing changes and shows
the lowest NO2 formation. In order to avoid toxic NO2
concentrations, an upper limit of 40 ppm (parts per
million) NO is recommended for continuous NO inhalation
(20,21). The generation of NO2 in the ventilator circuit is
directly proportional to the concentration of NO and O2
and inversely proportional to the TGF (total gas flow) and
MV (minute ventilation) but uninfluenced by the TGF/MV
ratio. NO at 80 ppm, but not 20 or 40 ppm in FiO2
(fraction of inspired oxygen) of 0.6, generates toxic NO2
irrespective of TGF, MV or TGF/MV ratios (22). To

overcome the shortcomings, several techniques have been
developed to synchronize the delivery of nitric oxide with
inspiration, thereby decreasing the time that nitric oxide
can react with oxygen and more closely matching nitric
oxide delivery to patient flow demands. The reviewed
techniques were the delivery through a nebulizer-type
injection mechanism (23), the blending with air or
nitrogen before delivery into the inspiratory port of the
ventilator (24,25), and the injection through the digitally
controlled nitric oxide intake valves (19).
The Ohmeda INOvent Equipment, Nitric Oxide delivery
system (Datex-Ohmeda, Madison, WI, USA) is an
integrated, single unit designed for the delivery and
monitoring of inhaled nitric oxide (iNO). It uses an
inspiratory flow sensor to inject a synchronized and
proportional nitric oxide (NO) flow into the mechanical
ventilator circuit, and was also reviewed in the literature
(26,27). This system should deliver a constant NO
concentration independent of ventilator mode, minute
ventilation, fraction of inspired oxygen, or ventilator
brand. It should also minimize NO2 formation. NO
delivery by the Ohmeda INOvent delivery system and a
premixing NO delivery system were compared using two
ventilators (Puritan-Bennett 7200 and Servo 900C). NO
concentrations were measured within the trachea of an
attached lung model using a fast-response
chemiluminescence NO analyzer. NO concentrations were
also measured in the inspiratory limb using the
electrochemical analyzer of the Ohmeda INOvent. For
three NO concentrations (2, 5 and 20 ppm), the
ventilators were set for constant flow volume control
ventilation, pressure control ventilation, and spontaneous
breathing with pressure support ventilation or
synchronized intermittent mandatory ventilation.
Different tidal volumes (300, 500, 750 and 1,000 mL)
and inspiratory times (1 and 2 s) were evaluated. NO2
formation for both ventilators and delivery systems were
evaluated at 20 ppm and 95% FiO2. Regardless of
ventilatory pattern, both systems delivered a constant NO
concentration. The Ohmeda INOvent delivery system
provides a constant NO concentration independent of the
ventilatory pattern, and NO2 formation is minimal
(26,27).
Concentrations of nitric oxide and oxides of nitrogen
should be monitored continuously during inhaled NO
delivery. In breathing systems, nitrogen dioxide
production is increased with high nitric oxide and FiO2,
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and with lower minute ventilation and total gas flow in
the systems with higher internal volume (Siemens Servo
300; Siemens, Iselin, NJ, USA) (28).
2) Exhaled nitric oxide measurements: In human
breath nitric oxide is produced mainly by the nasopharynx
and sinuses (29). The pulmonary fraction of exhaled nitric
oxide (eNO) comes chiefly from the alveolar epithelium
and macrophages. The reference values for eNO were
obtained in a study of 159 healthy children from Padua,
Italy (30). The tidal breath method with a
chemiluminescence analyzer was used for the
measurements and no steady state levels were recorded.
The mean concentration of endogenous NO in orally
exhaled gas was 8.7 ppb (parts per billion) with no
gender difference. The mean value of nasal NO
concentration was 216 ppb. These levels were
independent of age, gender and lung function and can be
used to monitor airway inflammation in asthmatic
children (30,31).
The presence of asthma (32) or the rejection of a
transplanted lung (33) leads to an increase in pulmonary
eNO. The clinical utility of eNO measurement as an aid in
the assessment of asthma in the emergency department
was studied. A total of 52 adult patients with acute
asthma, 53 age and sex-matched controls and 8 patients
with stable asthma were enrolled (32). A significant
difference between the eNO levels of acute asthma
patients and controls was observed. Some 23 of the 53
patients with acute asthma versus 2 of the controls had
an eNO level higher than 15ppb. The eNO concentration
correlated with FEV1% (forced expiratory volume in one
second) and the blood eosinophil count in the group of 60
patients with acute and stable asthma. No relation
between eNO levels and serum IgE, self-reported
smoking or glucocorticoid use were reported. It is
concluded that the measurement of eNO is a promising
tool for assessing acute asthma (32-36).
B) iNO measurement by chemiluminescence and
electrochemical techniques:
Currently, chemiluminescence analyzers constitute the
analytical standard for monitoring concentrations of nitric
oxide and other oxides of nitrogen in the clinical setting.
The performance characteristics of several commercially
available chemiluminescence analyzers were compared
recently (17). Accurate analysis of NO in a continuous
flow system was only possible with the most rapid
response analyzer (270B NOA).
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On the other hand, electrochemical detectors are
cheaper, smaller, and sufficiently sensitive to monitor
nitric oxide concentrations in the range between 5 ppm
and 80 ppm (23). Different pressure and varying ranges
of humidity influence the performance of electrochemical
detectors and clinicians should be aware of this possible
hazard. Electrochemical monitors use a simple
electrochemical principle for the detection of NO. The
monitored air passes through a plastic membrane into a
liquid acid electrode. The electrolyte solution contains the
sensing electrode (anode), a counter electrode (cathode)
and a reference electrode. The voltage between the anode
and cathode is kept constant and the current flowing
through the sensor is proportional to the amount of
reacting NO (37).
The Sensor Stik (Model 4586, Exidyne
Instrumentation Technologies, Exton, Pennsylvania, USA)
consists of a modular electrochemical sensor in a
cylindrical tube with a liquid crystal display. The monitor
weighs about 540 g without the energy supply and runs
on a separate DC energy supply (at least 24 V). The
sensor is capable of operating continuously for more than
12 months in the presence of 50 ppm NO (38). The
electrochemical reaction at the electrode is as follows:
+
NO + 2H2O → HNO3 + 3H + 3e
The PAC II (Drager AG, Lubeck, Germany) is a
compact personal monitor, which contains the sensor
unit, the liquid crystal display and a power unit (9 volt
battery). The weight of the complete monitor is 280 g.
The electrochemical reaction at the electrode is as
follows:
NO + H O → NO + 2H+ + 2e2

3

The PAC II is ready for operation a few seconds
following turning it on. No time consuming calibration is
necessary. Although both NO monitors provided an
accurate and reproducible method for measuring gaseous
NO, the Sensor Stik could not detect rapid decreases in
NO levels; therefore it is not recommended for clinical use
(38). Measurements of NO regression analysis showed a
close relationship between the two analyzers (38).
Electrochemical devices are more likely to be used in the
clinical setting because of their smaller size and quiet
operation (38).
One of the new electrochemical monitors was
developed by Carter et al. (39). (Printer NO; Micro
Medical Limited, Chatham, Kent, England. Also sold as
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Sensor NO; Sensormedics Corporation, California, USA.).
Printer NO was compared to a chemiluminescence
analyzer (42 H Thermo Environmental Instruments Inc.,
Franklin, Massachusetts, USA). The printer NO is small
and is easy to use and to calibrate. It has sufficient
accuracy to be of clinical use in the administration of NO
(39).
A comparison of electrochemical detector (ECD)
versus chemiluminescence detector (CLD) monitoring
techniques showed agreement between the instruments
within approximately 2 ppm, with the ECD averaging a
higher reading than the calculated or CLD measured
values. A 2 ppm discrepancy between the instruments is
considered to be clinically acceptable. The instruments
could be used interchangeably for clinical purposes to
measure NO, and the ECD was preferable to the CLD for
measuring NO2 (40).
A micro carbon electrode for monitoring NO: This
new NO probe is a combination of a micro carbon fibre
working electrode (10 micron diameter), a platinum
counter electrode and a silver/silver chloride (Ag/AgCl)
reference electrode. The carbon fibre working electrode
is covered with a Nafion cation exchange membrane (41).
The NO to N2O reduction current peak is about 1.35 V
against the Ag/AgCl electrode. The current outputs are
linearly related to dissolved NO concentrations in the 210 micromolar range. The Nafion membrane prevents
interference by NO and amino acids at physiological pH
(pH: 7.4). To improve sensitivity, pulse amperometry
was used. Charge outputs are linear to the dissolved NO
in the 50-350 nanomolar range. The carbon fiber

electrode has the potential of being miniaturized to a
smaller electrode, which may enable the detection of NO
released from the subendothelial space (41).
On-line recording of NO in breath by laser
magnetic resonance: Laser magnetic resonance
spectroscopy is a sensitive and isotope-selective technique
for determining low concentrations of gaseous free
radicals with high time resolution. This technique is used
to analyze the NO concentration profile while
simultaneously measuring the flow and expired volume
during several single breathing cycles (42).

Conclusion
Over the last ten years, significant discoveries about
the biology and physiology of nitric oxide were presented
to the scientific world. These findings encouraged
clinicians to demonstrate the beneficial effects of nitric
oxide on their patients. Nitric oxide is a selective
pulmonary vasodilator with minimal adverse effects.
Precise dosing and careful monitoring would help in the
conduct and validation of randomized trials. The standard
method is chemiluminescence analysis. Electrochemical
systems were recently reported in the literature. They are
relatively inexpensive and are regularly used for personal
or industrial NO monitoring. As nitric oxide gains wider
use in hospitals, clinicians must be familiar with its
pharmacophysiology, monitoring and delivery systems.
Its various clinical applications and side effects, to ensure
safe and effective therapy, will be discussed in a
subsequent study.
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